178 USE OF A NEW INTRAVAGINAL DEVICE TO RELEASE PROGESTERONE IN FIXED-TIME EMBRYO TRANSFER EMBRYO RECIPIENTS
| Autor: | F. A. Braga, Ed Hoffmann Madureira, F. J. D. Pardo, Cecilia Constantino Rocha, A. Kehrle, P. H. P. Miguez, José Pimentel |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment media_common.quotation_subject Reproductive technology Biology chemistry.chemical_compound Endocrinology Animal science Internal medicine Genetics medicine Molecular Biology Ovulation media_common Pregnancy Artificial insemination Embryo culture medicine.disease Embryo transfer Pregnancy rate Reproductive Medicine chemistry Estradiol benzoate Animal Science and Zoology Developmental Biology Biotechnology |
| Zdroj: | Reproduction, Fertility and Development. 22:247 |
| ISSN: | 1031-3613 |
| Popis: | Progestagen-releasing devices are commonly used for fixed-time artificial insemination and fixed-time embryo transfer (FTET). The aim of this study was to evaluate the efficacy of a new progesterone-releasing intravaginal device made of poly(3-hydroxy)butyrate-valerate copolymer (PHB-V) and poly-ϵ-caprolactone (PCL; Progestar®, Innovare, São Paulo, Brazil) to synchronize crossbredcows and heifers for FTET by determining ovulation, conception, and pregnancy rates. A total of 205 recipients ranging in age from 2 to 8 years (heifers, n = 77; non-suckled cows, n = 69; suckled cows, n = 59) were used on 3 different farms during February, March, and April 2008. The experimental design was a generalized block design (cyclicity, body condition score, postpartum interval, and animal category, i.e. heifers, suckled, or non-suckled cows), with 2 different synchronization treatments for FTET (Progestar® v. Crestar®). Cows were assigned to either Crestar® (norgestomet ear implants; Intervet Schering-Plough, Kenilworth, NJ, USA; n = 103) or Progestar® (PHB-V; n = 102) treatments. All groups were treated with 2 mg of estradiol benzoate i.m. (Innovare) and received the intravaginal or auricular device according to their group (Day 0). Together with P4 device withdrawal (Day 8), all animals received 400 IU of eCG i.m. (Novormon®, Schering-Plough) and 500 μg i.m. of PGF2α, (Sincrocio®, Ouro Fino, Brasil). On Day 9, all cows were treated with 1 mg of estradiol benzoate (Innovare) and the innovulation was performed on Day 17. Embryos were maintained at 37°C during the innovulation period. The percentage of usable recipients (AR) based on the presence of a functional CL on the day of embryo transfer, conception rate (numbers of pregnant recipients of the total number transferred; CR), and pregnancy rate (numbers of pregnant recipients of the total number synchronized; PR) were determined by ultrasonography 23 days after embryo transfer. Data were submitted to ANOVA (PROC GLM, SAS Institute Inc., Cary, NC, USA) and significant differences were considered to have a P-value of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|